123 related articles for article (PubMed ID: 19900441)
1. Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor.
Yarkov AV; Der TC; Joyce JN
Eur J Pharmacol; 2010 Feb; 627(1-3):167-72. PubMed ID: 19900441
[TBL] [Abstract][Full Text] [Related]
2. Age-related differences in MK-801 induced behaviors in dopamine D3 receptor knock out mice.
Iarkov AV; Der TC; Joyce JN
Eur J Pharmacol; 2010 Feb; 627(1-3):177-84. PubMed ID: 19909735
[TBL] [Abstract][Full Text] [Related]
3. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
[TBL] [Abstract][Full Text] [Related]
4. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
[TBL] [Abstract][Full Text] [Related]
5. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats.
Criswell HE; Johnson KB; Mueller RA; Breese GR
J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756
[TBL] [Abstract][Full Text] [Related]
6. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
7. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
8. Cocaine-induced locomotor activity and cocaine discrimination in dopamine D2 receptor mutant mice.
Chausmer AL; Elmer GI; Rubinstein M; Low MJ; Grandy DK; Katz JL
Psychopharmacology (Berl); 2002 Aug; 163(1):54-61. PubMed ID: 12185400
[TBL] [Abstract][Full Text] [Related]
9. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
Domino EF; Sheng J
J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
[TBL] [Abstract][Full Text] [Related]
10. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
[TBL] [Abstract][Full Text] [Related]
11. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice.
Risbrough VB; Masten VL; Caldwell S; Paulus MP; Low MJ; Geyer MA
Neuropsychopharmacology; 2006 Nov; 31(11):2349-58. PubMed ID: 16855533
[TBL] [Abstract][Full Text] [Related]
12. MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors.
Ho YJ; Chen KH; Tai MY; Tsai YF
Pharmacol Biochem Behav; 2004 Mar; 77(3):641-6. PubMed ID: 15006477
[TBL] [Abstract][Full Text] [Related]
13. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
[TBL] [Abstract][Full Text] [Related]
14. Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
Scorza MC; Castañé A; Bortolozzi A; Artigas F
Neuropharmacology; 2010; 59(1-2):112-20. PubMed ID: 20412811
[TBL] [Abstract][Full Text] [Related]
15. Behavioral and biochemical responses to d-amphetamine in MCH1 receptor knockout mice.
Smith DG; Qi H; Svenningsson P; Wade M; Davis RJ; Gehlert DR; Nomikos GG
Synapse; 2008 Feb; 62(2):128-36. PubMed ID: 18000809
[TBL] [Abstract][Full Text] [Related]
16. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration.
Li T; Hou Y; Yan CX; Chen T; Zhao Y; Li SB
Neurosci Lett; 2010 Nov; 485(3):256-60. PubMed ID: 20849922
[TBL] [Abstract][Full Text] [Related]
18. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
19. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice.
Villégier AS; Drouin C; Bizot JC; Marien M; Glowinski J; Colpaërt F; Tassin JP
Synapse; 2003 Dec; 50(4):277-84. PubMed ID: 14556232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
